The pharmaceutical Industry is a multibillion market consisting of innovator drugs & generics. The pharmaceutical market consists of a companies involved in the research, development, manufacturing and commercialization of drugs for human & animal use. Geographically, biologics have registered near double digit annual growth rate, whereas, the pharmaceutical drugs registered only single digit annual growth rate, in the past five years. This double digit growth was largely fuelled by the substantial investments of the major pharmaceutical companies, who realized the potential of the market quite early. Biologics are defined as pharmaceutical products obtained from living cells or micro-organisms. These are complex & large molecules consisting of proteins, peptides, nucleic acids, sugars, cellular structures or a combination of these.

1. GLOBAL BIOLOGICS DRUG DISCOVERY MARKET ANALYSIS AND FORECAST, (2017-2025)
(Focus on Method/Phase, Product Type, Manufacturer Type and Competitive Landscape)
1 The Research Scope and Methodology
1.1 Scope of the Report
The report constitutes of an in-depth study of the global biologics drug discovery
market, including a thorough analysis of the product across different regions. The
study also presents a detailed analysis of the market dynamics and the estimation for
market value over the forecast period, 2017 to 2025.
The purpose of the study is to gain a holistic view of the global biologics drug discovery
market in terms of various factors influencing it like recent trends, technological
advancements, and regulatory aspects of the market. In addition, the study also
comprises of exhaustive information on the product shortcomings, unmet needs,
competitive landscape, restraints and opportunities and the other vital information
with respect to different products. The scope of this report is centred upon conducting a
detailed study of the solutions allied with the market. The market has been segmented
into ‘Product’, ‘Phase’, ‘Manufacture’, and ‘Region’. Moreover, the global biologics drug
discovery market report deliberates in detail, the analysis of all the macro micro
factors. It also evaluate the opportunities in the market for stakeholders and provide
details of a competitive landscape for market leaders.
Key learnings of this research study are as following: -
• To understand the competitive landscape in the Biologics Drug Discovery market in
terms of leading players
 sales@bisresearch.com www.bisresearch.com 1

2. BIS Research Analysis
Figure 1 Key Elements Considered
 sales@bisresearch.com www.bisresearch.com 2
In-Depth Market Dynamics Analysis
Exhaustive Product Segmentation
Comprehensive Competitive Insights
Detailed Market Share Analysis
Extensive Coverage of Market Players
Thorough Analysis of Business Opportunities
• To identify the geographical setting holding the largest market share in the market
• To gain insights in terms of current regulations, directives, laws and standards etc. in this space
• To understand the market dynamics (Drivers, Challenges and Opportunities) for different
geographical location
• To estimate the market share, growth and value of the Biologics Drug Discovery market during the
forecast period
Report coverage of the global Biologics Drug Discovery market includes key elements considered
for the detailed analysis of the market:
• Market Overview provides an in depth analysis of the global Biologics Drug Discovery market
scenario, economic outlook, technology trends, and legal trends
• Market Dynamics: Drivers, Challenges and Opportunities related to the global Biologics Drug
Discovery market
• Competitive Landscape provides a comprehensive understanding of the business environment of
the market, growth matrix, and market share analysis, among others
• An in-depth analysis of the different product divisions across various regions consists of valuable
insights into the trend followed in the market

3. BIS Research Analysis
The global Biologics Drug Discovery market is further segmented as below:
Figure 2 Global Biologics Market Segmentation
 sales@bisresearch.com www.bisresearch.com 3
Product
• Monoclonal Antibodies
• Recombinant Proteins
• Other Biologics
Phase
• Target
Identification/Validation
• Hit Generation
• Lead Identification
• Lead Optimization
Manufacture
• In-House
• Outsourced
Geography
• North America
• Europe
• Asia Pacific
• Rest Of the World
1.2 BIS Research Market Research Methodology
The research methodology design adopted for this specific study includes a mix of data collected
from primary and secondary sources. Both primary sources (in-house experts, industry leaders and
market players) and secondary sources (a host of paid and unpaid databases) along with analytical
tools have been used exhaustively to build the forecast and predictive models.

4. BIS Research Analysis
Figure 3 BIS Research Market Research Methodology
 sales@bisresearch.com www.bisresearch.com 4
STUDYING THE MARKET STRUCTURE
IDENTIFY MARKET, TECHNOLOGY AND COMPETITOR TRENDS
INTEGRATE INFORMATION
RESEARCH APPROACH
DATABASE FOR KEY INDUSTRY PARTICIPANTS (DKIP) PREPARATION1.
DISCUSSION GUIDE PREPARATION2.
SCHEDULING AN APPOINTMENT3.
CALL EXECUTION4.
DOCUMENTATION5.
Mainly used to obtain key information about the industry’s value
chain, the total pool of key players
Understand market classification, and segmentation according to
industry trends to the bottom-most level, regional markets, and key
developments from both market- and technology-oriented
perspectives
The primary sources from the supply side include industry experts such as CEOs, vice presidents,
marketing directors, technology and innovation directors, and related key executives from various
vendors providing technology solutions, associated service providers, and system integrators
operating in the targeted regions.
E.g. CIO’s, VP, Director New Product Development, Director –operations
A detailed questionnaire is shared with the primary respondent covering all the aspects related to
the report topic
Appointments are scheduled with CIO’s, VP – healthcare companies, Director with prior
appointments and the discussion guide is shared with the primary respondent prior to the call
Integrate information within relevant documents to form launch pad
for primary research
A roundtable discussion is held with the KIP with the aim to gather first hand information about the
technology, recent developments in the technology and future outlook/ growth or decline
The interview is recorded and the information gathered in put on the drawing board with the
information collected through secondary research.
RESELLERS
MSP’s
CONSULTANT
END USER
VENDORS
POTENTIAL
RESPONDENTS
PRIMARY RESEARCHSECONDARY RESEARCH
Primary Data Sources
The key data points taken from Primary Sources includes:
• Validation and Triangulation of all the numbers and graphs
• Validation of report segmentation and key qualitative findings
• Understanding the competitive landscape
• Understanding and considering the market dynamics factors for various market segment and
sub-segment
• Validation of impact analysis of macro and micro factors in different countries
• Percentage split of individual markets for geographical analysis
Secondary Data Sources
The research study involves the usage of extensive secondary sources such as databases, company
websites, and annual reports, among others.

5. The key data points taken from secondary sources include:
• Segmentation breakups, split-ups, and percentage shares
• Data for market value
• Key industry trends of the top players of the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of
innovation
• Quantitative data for mathematical and statistical calculations
The following figure exhibits the methodology adopted for estimating the global Biologics Drug
Discovery market:
The following figure exhibits key secondary data sources considered in this report:
Figure 4 Secondary Data Sources
 sales@bisresearch.com www.bisresearch.com 5
SECONDARY DATA SOURCES
GOVERNMENT AND REGULATORY
SOURCES
The Centre for Disease Control (CDC)
The World Health Organization (WHO)
The National Health Services (NHS)
The National Center for Biotechnology
Information (NCBI)
The Food Drug Administration of United
States (U.S. FDA)
STOCK ANALYST WEBSITES
Seeking Alpha
Yahoo Finance
Wiki Finance
The Wall Street Journal
COMPANY SOURCES
Annual Reports
Press Releases
SEC Filings
Investor Presentations
Financial Disclosures
PUBLIC AND PRIVATE DATABASES
Medline
PubMed
National Library of Medicine
ProQuest
Thin Database
CMS Datasets
Medicare Beneficiaries Database
Oxon Epidemiology
BIS Research Analysis

6.  sales@bisresearch.com www.bisresearch.com 6
Figure 5 Top Down and Bottom Up Approach
Having estimated the global market size, the forecast employs a set of macro factors such as the
population, disease prevalence rate, population, healthcare expenditure, disposable income, and
Gross Domestic Product (GDP), among others.
Assumptions and Limitations
The following figure exhibits the standard assumptions and limitations which have been followed
throughout the research study of the global Biologics Drug Discovery market:
Total global Biologics Drug Discovery market
size ($million)
Percent split for the product type
and sub-types of global Biologics
Drug Discovery market
Geographical split
Summation of x y
Average selling price (ASP) for
each type of product (Y)
Products into number of units (X)
Analysis of macro micro factors
Market
value of
global Biologics
Drug Discovery
market
Regional and
country-wise market
for each sub-
segment
BIS Research Analysis
Note: The above approach has been followed for the market estimation of all the product segments related to Biologics Drug Discovery
market

7.  sales@bisresearch.com www.bisresearch.com 7
Figure 6 Assumptions and Limitations
CURRENCY CONVERSION
• The base currency considered for this study is U.S. $
• In the Company Profiles section, for the companies
having revenues in any other currencies, is converted
in to U.S. $
• The currencies other than U.S. $ are converted to U.S.
$ for all statistical calculations considering the average
conversion rate for the particular year
• The currency conversion rate is taken from historical
exchange rate of Oanda website
LIMITATIONS
• Technologies currently used are expected to persist
through the forecast with no major breakthrough in
technology
• The economic downturn in future was not taken
under consideration for market estimation and
forecast
AVERAGE SELLING PRICE (ASP)
• The ASP is calculated for the year 2016 and the
currency considered is U.S. $
• For calculating the ASP of the market products, the
weighted average of the list price of products has
been considered
ASSUMPTIONS FOR MARKET ESTIMATION
• The base year considered for the calculation of market
size was 2016. Instances where the market size for the
FY 2016 were not available from primary or secondary
sources, at such instances the values were estimated
based on the Delphi method.
• The historical year analysis was done from the FY 2010
to FY 2015 and the market size was estimated for the
FY 2016 and projected from the year 2017 to 2023
BIS Research Analysis

8. TABLE OF CONTENTS
Executive Summary
1. Report Scope
1.1. Scope of the Report
1.2. Global Biologics Drug Discovery Market Segmentation
1.3. Key Learnings
1.4. Research Methodology
1.4.1. Data Triangulation
1.4.2. Key Data Points from Secondary Sources
1.4.3. Key Data Points from Primary Sources
1.4.4. Top-Down Approach (Segmental Analysis)
1.4.5. Bottom-Up Approach (Segmental Analysis)
1.4.6. Assumptions and Limitations
1.4.7. Data and Prediction Modelling
2. Market Overview
2.1. Introduction
2.2. Market Dynamics
2.2.1. Market Drivers
2.2.2. Market Challenges
2.2.3. Market Opportunities
3. Industry Insights
3.1. Regulatory Scenario
3.2. Patent Landscape
4. Competitive Landscape
4.1. Share of Key Developments Strategies
4.1.1. Collaboration/ Partnership/ Joint Venture/ Licensing Agreement
4.1.2. Mergers Acquisitions
4.1.3. Business Expansion
4.1.4. Products/Platform/Services Launch
4.1.5. Others
4.2. Porter’s Five Forces Analysis
4.2.1. Bargaining Power of Suppliers
4.2.2. Bargaining Power of Buyers
4.2.3. Threat of New Entrants
4.2.4. Threat of Substitutes
4.2.5. Intensity of Competitive Rivalry
 sales@bisresearch.com www.bisresearch.com 8

9.  sales@bisresearch.com www.bisresearch.com 9
5. Global Biologics Drug Discovery Market, by Product
5.1. Small Molecule Vs. Biologicals
5.2. Biologicals
5.2.1. Monoclonal Antibodies
5.2.2. Recombinant Proteins
5.2.3. Other biologics
6. Global Biologics Drug Discovery Market, by Phase
6.1. Target Identification/Validation
6.1.1. Functional Genomics/Proteomics
6.1.2. Computational Approach/In-silico
6.1.3. Cell based Assay
6.1.4. Knock out studies/CRISPR/Cas9
6.1.5. Animal/Disease Based Models
6.2. Hit Generation
6.3. Lead Identification
6.4. Lead Optimization
7. Global Biologics Drug Discovery Market, by Manufacture Type
7.1. Type of Manufacturing
7.1.1. In-House Manufacturing
7.1.2. Advantages of Outsourcing Development
7.1.3. Outsourced Manufacturing
8. Global Biologics Drug Discovery Market, by Geography
8.1. Introduction
8.2. North America
8.3. Europe
8.4. Asia-Pacific
8.5. Rest Of the World
9. Company Profiles
9.1. Abbvie Inc.
9.2. Albany Molecular Research Inc.
9.3. Allergan plc.
9.4. Amgen Inc.
9.5. Aptuit
9.6. Atellas Pharma Inc.
9.7. AstraZeneca PLC
9.8. Bayer AG
9.9. Biocon Ltd.
9.10. Boehringer Ingelheim GmbH

10.  sales@bisresearch.com www.bisresearch.com 10
9.11. BRISTOL-MYERS SQUIBB COMPANY
9.12. Charles River Laboratories International, Inc.
9.13. Eli Lilly and Company
9.14. Evotec AG
9.15. F. Hoffmann-La Roche AG
9.16. GenScript
9.17. Gilead Sciences Inc.
9.18. GlaxoSmithKline Plc
9.19. JOHNSON JOHNSON
9.20. Laboratory Corporation of America Holdings
9.21. Merck KGaA
9.22. Merck CO., Inc.
9.23. Novartis AG
9.24. NOVO NORDISK
9.25. Pfizer Inc.
9.26. Sanofi
9.27. Teva Pharmaceuticals
9.28. WuXi Apptec

11. 16 sales@bisresearch.com www.bisresearch.com 11
DISCLAIMER
BIS Research provides valuable market intelligence to an exclusive group of customers in response
to orders. The report is licensed for the customer’s internal use only and is subject to restrictions
set henceforth. This document and its contents are confidential and may not be further distributed,
published or reproduced, in whole or in part, by any medium or in any form for any purpose, without
the express written consent of BIS Research. Customer will not disclose the contents of the report,
whether directly in any media or indirectly through incorporation in a database, marketing list, report
or otherwise, or use or permit the use of Information to generate any statistical or other information
that is or will be provided to third parties; or voluntarily produce Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information
is available. Any recommendation contained in this report may not be suitable for all investors or
businesses. The market conclusions drawn are necessarily based upon a number of estimates and
assumptions that, while considered reasonable by BIS Research as of the date of such statements, are
inherently subject to market fluctuations and business, economic and competitive uncertainties and
contingencies
For more details regarding permission, please contact us:
 Email: sales@bisresearch.com
 Tel: +1 650 228 0182